Market Access News | pharmaphorum

News

FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'

Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.

News

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.

News

Scholar Rock gets first drug approval as FDA okays Isembyld

Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.

News

Hengrui gets world-first okay for platelet drug hetrombopag

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

News

Reviews underway of first drug for rare disease MOGAD

Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.

News

Bayer moves Hyrnuo into frontline lung cancer treatment

Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.

FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'

FDA to decide on Takeda's psoriasis blockbuster hope in Q1

Scholar Rock gets first drug approval as FDA okays Isembyld

Hengrui gets world-first okay for platelet drug hetrombopag

Reviews underway of first drug for rare disease MOGAD

Bayer moves Hyrnuo into frontline lung cancer treatment

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks